Skip to main content
. 2022 Mar 9;12:203–209. doi: 10.1016/j.ibneur.2022.03.002

Table 1.

Summary of findings on SUMOylation pathway proteins in HD and polyQ disorders.

SUMOylation pathway protein Model Event Effect Ref.
PIAS1 zQ175 KI mice and HD patient-derived iPSCs KD DNA damage repair responses and normalized transcriptional profiles Morozko et al. (2021)
R6/2 mice KD and Overexpression Reduction of insoluble protein and phenotypic benefit Ochaba et al. (2016)
Rhes Striatal neuronal cells (STHdhQ7/Q7) or HD mutants (STHdhQ111/Q111) Rhes-mediated mHtt transport Facilitation of cell–cell transport of mHtt Sharma and Subramaniam (2019)
HEK293 cells Binding to mHtt mHtt increased disaggregation and cytotoxicity Subramaniam et al. (2009)
Rhes KO mice Binding to E1 and Ubc9 Ubc9 binding to Htt and cross-SUMOylation of E1 and Ubc9 Subramaniam et al. (2010)
Rhes KO N171-82Q mice mTORC1 signaling dysregulating Early striatal motor deficit Swarnkar et al. (2015)
STUbL Slx5 Yeast plasmids expressing 25Q and 103Q Htt Expression and transcriptional properties of aggregation-prone Htt constructs Reduced toxicity and abnormal transcriptional activity Ohkuni et al. (2018)
SUMO-1 NIID brain tissue and PC12 cells Localization into fibrils of tissues and nuclear inclusions Recruitment of SUMO-1 modified proteins into insoluble nuclear inclusions and proteasomal dysfunction Pountney et al. (2003)
PC12 cells SUMO-1 and atrophin-1co-transfection Accelerated aggregate formation and cell death Terashima et al. (2002)
Brain tissue (HD, DRPLA, SCA1 and MJD) and B05 transgenic mouse Increased SUMOylated proteins in cerebellar cortex SUMO-1 activation contributes to polyQ diseases Ueda et al. (2002)
Brain tissue (MSA) Cytoplasmic accumulation of α-synuclein, tau or HttQ74-GFP SUMO-1 colocalization with lysosomes related to glial protein aggregates and protein aggregation Wong et al. (2013)
SUMO-2 HeLa cells Htt SUMO-2 modification Decreased accumulation O’Rourke et al. (2013)

DRPLA: dentatorubral-pallidoluysian atrophy; E1: SUMO activating enzyme E1; GFP: green fluorescent protein; HD: Huntington’s disease; HEK: human embryonic kidney cells; Htt: huntingtin; iPSCs: induced pluripotent stem cells; KD: knockdown; KI: knock-in; KO: knockout; mHtt: mutant huntingtin; MJD: Machado-Joseph disease; MSA: multiple system atrophy; mTORC1: mechanistic target of rapamycin complex 1; NIID: neuronal intranuclear inclusion disease; PolyQ: polyglutamine; PIAS1: Protein Inhibitor of Activated STAT 1; Q: glutamine; Rhes: Ras homolog enriched in the striatum; SCA1: spinocerebellar ataxia type 1; STUbL: SUMO-targeted ubiquitin ligase; Ubc9: SUMO conjugating enzyme 9.